Recent advances in antibody-drug conjugates combined with immunotherapy for urothelial carcinoma
International Immunopharmacology · 2026-12 · 191 · 117616
DOI: 10.1016/j.intimp.2026.117616 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Immunopharmacology, 2026-12. Verfasst von Zijian Jiang und 1 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Yangtze University, Jingzhou 434020, China. Die Arbeit nennt 66 Literaturangaben. Gefördert von: National College Students Innovation and Entrepreneurship Training Program.
Abstract (Originalsprache)
Urothelial carcinoma (UC) remains a major malignancy of the urinary tract, with treatment options limited by platinum ineligibility, primary or acquired resistance, and treatment-related toxicity. Antibody-drug conjugates (ADCs) enable tumor-targeted delivery of highly potent cytotoxic agents and have demonstrated substantial activity in advanced UC. The combination of ADCs with immune checkpoint inhibitors (ICIs) has transitioned from experimental therapy to established clinical practice, most notably with enfortumab vedotin (EV) plus pembrolizumab and, in HER2-expressing disease in China, disitamab vedotin (RC48) plus toripalimab. Perioperative evidence has also matured, with phase III trials showing clinically meaningful improvements in event-free and overall survival for EV plus pembrolizumab in both cisplatin-ineligible and cisplatin-eligible muscle-invasive bladder cancer. This review integrates clinical evidence for ADC-ICI combinations across disease stages, discussing their mechanistic rationale, regimen-specific safety, biomarker development, resistance mechanisms, and emerging next-generation ADC platforms. We distinguish preclinical or mechanistic evidence from clinical efficacy and emphasize that pharmacologic synergy has not been established through indirect cross-trial comparisons. Although several biomarkers are biologically plausible, none have yet been prospectively validated as specific predictors of benefit from ADC-ICI combinations. We also discuss perioperative and bladder-sparing applications and identify priorities for treatment sequencing, toxicity surveillance, and biomarker-guided precision therapy in UC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Medicine, Yangtze University, Jingzhou 434020, China.
- School of Medicine, Yangtze University, Jingzhou 434020, China. Electronic address: milano062009@163.com.
Förderung
- National College Students Innovation and Entrepreneurship Training Program
Zitieren
APA
Jiang, Z., & Yang, M. (2026). Recent advances in antibody-drug conjugates combined with immunotherapy for urothelial carcinoma. International Immunopharmacology, 191, 117616. https://doi.org/10.1016/j.intimp.2026.117616
Vancouver
Jiang Z, Yang M. Recent advances in antibody-drug conjugates combined with immunotherapy for urothelial carcinoma. International Immunopharmacology. 2026;191:117616. doi:10.1016/j.intimp.2026.117616
BibTeX
@article{Jiang2026,
author = {Jiang, Zijian and Yang, Minlan},
title = {Recent advances in antibody-drug conjugates combined with immunotherapy for urothelial carcinoma},
journal = {International Immunopharmacology},
year = {2026},
volume = {191},
pages = {117616},
doi = {10.1016/j.intimp.2026.117616}
}
EUVIMED